SGLT-2 Inhibitors and Regenerative Cell Exhaustion.
Level V
Where this comes from
- Record sourced from PubMed, PMID 32302528.
- Also identified by DOI 10.1016/j.cmet.2020.04.003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In response to the Letter by Fadini, Hess et al. discuss the interpretation of their data and the details of the multiparametric analyses employed to measure the changes in circulating provascular cell content in patients with type 2 diabetes receiving empagliflozin compared to placebo treatment.
Medical subject headings
- Diabetes Mellitus, Type 2
- Sodium-Glucose Transporter 2 Inhibitors